Background: Von Hippel–Lindau(VHL) syndrome is a dominantly inherited multisystem cancer syndrome caused by a heterozygous mutation in the VHL tumor suppressor
The management of localized breast cancer has changed dramatically over the past three to four decades. Breastconserving therapy, which involved lumpectomy foll